Aviva Levina

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5894502/publications.pdf

Version: 2024-02-01

96	4,870	81434	107981
papers	citations	41 h-index	68 g-index

102	102	102	5164
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Advantageous Reactivity of Unstable Metal Complexes: Potential Applications of Metal-Based Anticancer Drugs for Intratumoral Injections. Pharmaceutics, 2022, 14, 790.	2.0	15
2	Urea Gel Electrophoresis in Studies of Conformational Changes of Transferrin on Binding and Transport of Non-Ferric Metal Ions. Gels, 2022, 8, 19.	2.1	6
3	Ruthenium(II)â€“Arene Thiocarboxylates: Identification of a Stable Dimer Selectively Cytotoxic to Invasive Breast Cancer Cells. ChemBioChem, 2020, 21, 1188-1200.	1.3	5
4	A Shortâ€Lived but Highly Cytotoxic Vanadium(V) Complex as a Potential Drug Lead for Brain Cancer Treatment by Intratumoral Injections. Angewandte Chemie, 2020, 132, 15968-15972.	1.6	8
5	Frontispiz: A Shortâ€Lived but Highly Cytotoxic Vanadium(V) Complex as a Potential Drug Lead for Brain Cancer Treatment by Intratumoral Injections. Angewandte Chemie, 2020, 132, .	1.6	0
6	Frontispiece: A Shortâ€Lived but Highly Cytotoxic Vanadium(V) Complex as a Potential Drug Lead for Brain Cancer Treatment by Intratumoral Injections. Angewandte Chemie - International Edition, 2020, 59, .	7.2	0
7	Vanadium(V/IV)â€“Transferrin Binding Disrupts the Transferrin Cycle and Reduces Vanadium Uptake and Antiproliferative Activity in Human Lung Cancer Cells. Inorganic Chemistry, 2020, 59, 16143-16153.	1.9	22
8	A Shortâ€Lived but Highly Cytotoxic Vanadium(V) Complex as a Potential Drug Lead for Brain Cancer Treatment by Intratumoral Injections. Angewandte Chemie - International Edition, 2020, 59, 15834-15838.	7.2	46
9	Vanadium(V) tris-3,5-di-tert-butylcatecholato complex: Links between speciation and anti-proliferative activity in human pancreatic cancer cells. Journal of Inorganic Biochemistry, 2019, 201, 110815.	1.5	25
10	Redox chemistry and biological activities of chromium(III) complexes. , 2019, , 281-321.		5
11	Hydrophobicity may enhance membrane affinity and anti-cancer effects of Schiff base vanadium(<scp>v</scp>) catecholate complexes. Dalton Transactions, 2019, 48, 6383-6395.	1.6	51
12	Transferrin Cycle and Clinical Roles of Citrate and Ascorbate in Improved Iron Metabolism. ACS Chemical Biology, 2019, 14, 893-900.	1.6	17
13	Reactivity and Transformation of Antimetastatic and Cytotoxic Rhodium(III)â€“Dimethyl Sulfoxide Complexes in Biological Fluids: An XAS Speciation Study. Inorganic Chemistry, 2019, 58, 4880-4893.	1.9	9
14	Synthesis, characterization and in vitro anti-cancer activity of vanadium-doped nanocrystalline hydroxyapatite. New Journal of Chemistry, 2019, 43, 17891-17901.	1.4	14
15	(Pentamethylcyclopentadienato)rhodium Complexes for Delivery of the Curcumin Anticancer Drug. European Journal of Inorganic Chemistry, 2017, 2017, 1812-1823.	1.0	16
16	Stabilities and Biological Activities of Vanadium Drugs: What is the Nature of the Active Species?. Chemistry - an Asian Journal, 2017, 12, 1692-1699.	1.7	68
17	High cytotoxicity of vanadium(IV) complexes with 1,10-phenanthroline and related ligands is due to decomposition in cell culture medium. Journal of Biological Inorganic Chemistry, 2017, 22, 663-672.	1.1	51
18	Biospectroscopy for studying the influences of anti-diabetic metals (V, Cr, Mo, and W) to the insulin signaling pathway. AIP Conference Proceedings, 2017, , .	0.3	2

#	Article	IF	Citations
19	Speciation of metal drugs, supplements and toxins in media and bodily fluids controls in vitro activities. Coordination Chemistry Reviews, 2017, 352, 473-498.	9.5	181
20	Synthesis, reactivities and anti-cancer properties of ruthenium(II) complexes with a thiaether macrocyclic ligand. Inorganica Chimica Acta, 2017, 454, 128-138.	1.2	7
21	Biospeciation of Cr(III) Nutritional Supplements in Biological Fluids. Makara Journal of Science, 2017, 21, .	1.1	2
22	Mass Spectrometry Analysis of Chromium-Binding Low-Molecular-Weight Serum Fractions. Journal of Pure and Applied Chemistry Research, 2017, 6, 100-111.	0.1	0
23	Binding of Chromium(III) to Transferrin Could Be Involved in Detoxification of Dietary Chromium(III) Rather than Transport of an Essential Trace Element. Angewandte Chemie, 2016, 128, 8236-8239.	1.6	5
24	Carcinogenic Chromium(VI) Compounds Formed by Intracellular Oxidation of Chromium(III) Dietary Supplements by Adipocytes. Angewandte Chemie - International Edition, 2016, 55, 1742-1745.	7.2	54
25	Comparison of KP1019 and NAMI-A in tumour-mimetic environments. Metallomics, 2016, 8, 762-773.	1.0	37
26	XAS spectroelectrochemistry: reliable measurement of X-ray absorption spectra from redox manipulated solutions at room temperature. Journal of Synchrotron Radiation, 2016, 23, 743-750.	1.0	16
27	Binding of Chromium(III) to Transferrin Could Be Involved in Detoxification of Dietary Chromium(III) Rather than Transport of an Essential Trace Element. Angewandte Chemie - International Edition, 2016, 55, 8104-8107.	7.2	43
28	Carcinogenic Chromium(VI) Compounds Formed by Intracellular Oxidation of Chromium(III) Dietary Supplements by Adipocytes. Angewandte Chemie, 2016, 128, 1774-1777.	1.6	7
29	Simultaneous biosynthesis of putrebactin, avaroferrin and bisucaberin by Shewanella putrefaciens and characterisation of complexes with iron(III), molybdenum(VI) or chromium(V). Journal of Inorganic Biochemistry, 2016, 162, 207-215.	1.5	27
30	EXAFS and EPR Studies of the Alkene Oxidation Catalyst Species trans-[CrIII(bpb)(L)2]n+ and CrV Oxidation Products (bpb=N,N'-Bis(2-pyridinecarboxamido)-1,2-benzene). Australian Journal of Chemistry, 2015, 68, 581.	0.5	3
31	Reactivity and Speciation of Anti-Diabetic Vanadium Complexes in Whole Blood and Its Components: The Important Role of Red Blood Cells. Inorganic Chemistry, 2015, 54, 7753-7766.	1.9	67
32	Vanadium(V) and -(IV) complexes of anionic polysaccharides: Controlled release pharmaceutical formulations and models of vanadium biotransformation products. Journal of Inorganic Biochemistry, 2015, 147, 227-234.	1.5	15
33	Biotransformations of Antidiabetic Vanadium Prodrugs in Mammalian Cells and Cell Culture Media: A XANES Spectroscopic Study. Inorganic Chemistry, 2015, 54, 6707-6718.	1.9	53
34	Influence of an anti-metastatic ruthenium(iii) prodrug on extracellular proteinâ€“protein interactions: studies by bio-layer interferometry. Inorganic Chemistry Frontiers, 2014, 1, 44-48.	3.0	24
35	Reactivityâ€“activity relationships of oral anti-diabetic vanadium complexes in gastrointestinal media: an X-ray absorption spectroscopic study. Metallomics, 2014, 6, 1880-1888.	1.0	37
36	Vanadium Speciation by XANES Spectroscopy: A Threeâ€Dimensional Approach. Chemistry - A European Journal, 2014, 20, 12056-12060.	1.7	42

#	Article	IF	Citations
37	Solid-State Structural Studies of Chromium(III) Nicotinato Nutritional Supplements. Inorganic Chemistry, 2014, 53, 10685-10694.	1.9	13
38	Biotransformations of Anticancer Ruthenium(III) Complexes: An Xâ€Ray Absorption Spectroscopic Study. Chemistry - A European Journal, 2013, 19, 3609-3619.	1.7	63
39	Isolation, Characterization, and Nuclease Activity of Biologically Relevant Chromium(V) Complexes with Monosaccharides and Model Diols. Likely Intermediates in Chromium-Induced Cancers. Inorganic Chemistry, 2013, 52, 4282-4292.	1.9	19
40	Synthesis and Characterization of a Chromium(V) cis-1,2-Cyclohexanediolato Complex: A Model of Reactive Intermediates in Chromium-Induced Cancers. Inorganic Chemistry, 2012, 51, 11238-11240.	1.9	15
41	X-ray-induced photo-chemistry and X-ray absorptionÂspectroscopy of biological samples. Journal of Synchrotron Radiation, 2012, 19, 875-886.	1.0	141
42	Chemical alterations to murine brain tissue induced by formalin fixation: implications for biospectroscopic imaging and mapping studies of disease pathogenesis. Analyst, The, 2011, 136, 2941.	1.7	163
43	Metal-based anti-diabetic drugs: advances and challenges. Dalton Transactions, 2011, 40, 11675.	1.6	109
44	Studies on the Biotransformations and Biodistributions of Metal-Containing Drugs Using X-Ray Absorption Spectroscopy. Current Topics in Medicinal Chemistry, 2011, 11, 553-571.	1.0	51
45	Biomedical applications of X-ray absorption and vibrational spectroscopic microscopies in obtaining structural information from complex systems. Radiation Physics and Chemistry, 2010, 79, 176-184.	1.4	34
46	Characterization of a Ruthenium(III)/NAMIâ€A Adduct with Bovine Serum Albumin that Exhibits a High Antiâ€Metastatic Activity. Angewandte Chemie - International Edition, 2010, 49, 1661-1664.	7.2	111
47	Imaging Metals in Proteins by Combining Electrophoresis with Rapid X-ray Fluorescence Mapping. ACS Chemical Biology, 2010, 5, 577-587.	1.6	52
48	Formation and Reactivity of Chromium(V)â^'Thiolato Complexes: A Model for the Intracellular Reactions of Carcinogenic Chromium(VI) with Biological Thiols. Journal of the American Chemical Society, 2010, 132, 8720-8731.	6.6	41
49	Silicon nitride as a versatile growth substrate for microspectroscopic imaging and mapping of individual cells. Molecular BioSystems, 2010, 6, 1316.	2.9	72
50	Recent developments in ruthenium anticancer drugs. Metallomics, 2009, 1, 458.	1.0	531
51	Chromium in Cancer and Dietary Supplements. Biological Magnetic Resonance, 2009, , 551-579.	0.4	8
52	Chemical Properties and Toxicity of Chromium(III) Nutritional Supplements. Chemical Research in Toxicology, 2008, 21, 563-571.	1.7	190
53	Reactivity of Chromium(III) Nutritional Supplements in Biological Media: An X-Ray Absorption Spectroscopic Study. Inorganic Chemistry, 2008, 47, 4299-4309.	1.9	65
54	A potential role for protein tyrosine phosphatase inhibition by a RuIIIâ€“edta complex (edta =) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 62 T	2.2	32

#	Article	IF	Citations
55	Post-translational Regulation of Human Indoleamine 2,3-Dioxygenase Activity by Nitric Oxide*. Journal of Biological Chemistry, 2007, 282, 23778-23787.	1.6	88
56	Redox chemistry and biological activities of chromium(III) complexes. , 2007, , 225-256.		13
57	X-ray Absorption and EPR Spectroscopic Studies of the Biotransformations of Chromium(VI) in Mammalian Cells. Is Chromodulin an Artifact of Isolation Methods? [J. Am. Chem. Soc.2007,129, 1065â˜’1075].. Journal of the American Chemical Society, 2007, 129, 9832-9832.	6.6	4
58	X-ray Absorption and EPR Spectroscopic Studies of the Biotransformations of Chromium(VI) in Mammalian Cells. Is Chromodulin an Artifact of Isolation Methods?. Journal of the American Chemical Society, 2007, 129, 1065-1075.	6.6	72
59	Reactivity of potential anti-diabetic molybdenum(VI) complexes in biological media: A XANES spectroscopic study. Journal of Inorganic Biochemistry, 2007, 101, 1586-1593.	1.5	29
60	Charge Distribution in Chromium and Vanadium Catecholato Complexes:â€‰ X-ray Absorption Spectroscopic and Computational Studies. Inorganic Chemistry, 2006, 45, 4743-4754.	1.9	45
61	Binding of chromium(VI) to histones: implications for chromium(VI)-induced genotoxicity. Journal of Biological Inorganic Chemistry, 2006, 11, 225-234.	1.1	49
62	The EPR pattern of CrV complexes of d-ribose derivatives. Polyhedron, 2005, 24, 1079-1085.	1.0	8
63	Mechanistic studies of relevance to the biological activities of chromium. Coordination Chemistry Reviews, 2005, 249, 281-298.	9.5	219
64	Three-dimensional structure determination using multiple-scattering analysis of XAFS: applications to metalloproteins and coordination chemistry. Coordination Chemistry Reviews, 2005, 249, 141-160.	9.5	81
65	Time-dependent uptake, distribution and biotransformation of chromium(VI) in individual and bulk human lung cells: application of synchrotron radiation techniques. Journal of Biological Inorganic Chemistry, 2005, 10, 105-118.	1.1	67
66	Chromium(V) Complexes of Hydroxamic Acids:â€‰ Formation, Structures, and Reactivities. Inorganic Chemistry, 2005, 44, 2934-2943.	1.9	39
67	Chromium(V) Peptide Complexes:Â Synthesis and Spectroscopic Characterization. Inorganic Chemistry, 2005, 44, 1044-1053.	1.9	23
68	Bonding in HNO-Myoglobin as Characterized by X-ray Absorption and Resonance Raman Spectroscopies. Journal of the American Chemical Society, 2005, 127, 814-815.	6.6	85
69	X-ray Absorption Spectroscopic and Electrochemical Studies of Tris(catecholato(2â˜))chromate(V/IV/III) Complexes. Angewandte Chemie - International Edition, 2004, 43, 462-465.	7.2	27
70	Biomimetic Oxidation of Chromium(III): Does the Antidiabetic Activity of Chromium(III) Involve Carcinogenic Chromium(VI)?. Angewandte Chemie - International Edition, 2004, 43, 4504-4507.	7.2	82
71	Solution Structures of Chromium(VI) Complexes with Glutathione and Model Thiols. Inorganic Chemistry, 2004, 43, 324-335.	1.9	65
72	X-ray Absorption Spectroscopic Studies of Chromium(V/IV/III)â˜’ 2-Ethyl-2-hydroxybutanoato(2â˜’/1â˜’) Complexes. Inorganic Chemistry, 2004, 43, 1046-1055.	1.9	35

#	Article	IF	Citations
73	Synthesis and Characterization of a Chromium(V)cis-Dioxo Bis(1,10-phenanthroline) Complex and Crystal and Molecular Structures of Its Chromium(III) Precursor. Inorganic Chemistry, 2004, 43, 7844-7856.	1.9	35
74	Structure and Reactivity of a Chromium(V) Glutathione Complex1. Inorganic Chemistry, 2003, 42, 767-784.	1.9	73
75	Reactive intermediates formed during the reactions of chromium(VI) with glutathione: Which species are responsible for the DNA damage?. Journal of Inorganic Biochemistry, 2003, 96, 177.	1.5	7
76	Synthesis of a Pyridinium Bis[citrato(2â¯)]oxochromate(V) Complex and Its Ligand-Exchange Reactions. Inorganic Chemistry, 2003, 42, 6458-6468.	1.9	23
77	X-ray Absorption Spectroscopic Studies of Chromium Nitroso Complexes. Crystal and Molecular Structure of (Ph4P)3[Cr(NO)(NCS)5]Â·2.4(CH3)2CO. Inorganic Chemistry, 2003, 42, 5392-5398.	1.9	25
78	Redox and ligand-exchange chemistry of chromium(vi/v)-methyl glycoside systems. Dalton Transactions RSC, 2002, , 3206.	2.3	22
79	An Investigation of the Chromium Oxidation State of a Monoanionic Chromium Tris(catecholate) Complex by X-ray Absorption and EPR Spectroscopies. Inorganic Chemistry, 2001, 40, 214-217.	1.9	24
80	Disproportionation of a Model Chromium(V) Complex Causes Extensive Chromium(III)-DNA Binding in Vitro. Chemical Research in Toxicology, 2001, 14, 946-950.	1.7	32
81	Chromium(VI) Reduction by Catechol(amine)s Results in DNA Cleavage in Vitro:â€‰ Relevance to Chromium Genotoxicity. Chemical Research in Toxicology, 2001, 14, 500-510.	1.7	44
82	Studies on the genotoxicity of chromium: from the test tube to the cell. Coordination Chemistry Reviews, 2001, 216-217, 537-582.	9.5	185
83	Disproportionation and Nuclease Activity of Bis[2-ethyl-2-hydroxybutanoato(2â¯)]oxochromate(V) in Neutral Aqueous Solutions1. Inorganic Chemistry, 2000, 39, 385-395.	1.9	53
84	Characterization and X-ray Absorption Spectroscopic Studies of Bis[quinato(2â¯)]oxochromate(V)1. Inorganic Chemistry, 2000, 39, 990-997.	1.9	38
85	Reactions of Chromium(VI/V/IV) with Bis(O-ethyl-l-cysteinato-N,S)zinc(II):Â A Model for the Action of Carcinogenic Chromium on Zinc-Finger Proteins1. Journal of the American Chemical Society, 2000, 122, 6208-6216.	6.6	42
86	X-Ray absorption spectroscopic studies of the Cr(IV) 2-ethyl-2-hydroxybutanoato(1â¯) complexâ€. Chemical Communications, 1999, , 2339-2340.	2.2	9
87	In Vitro Plasmid DNA Cleavage by Chromium(V) and -(IV) 2-Hydroxycarboxylato Complexes. Chemical Research in Toxicology, 1999, 12, 371-381.	1.7	57
88	An EPR Spectroscopic Study of Chromium(V) Oxalato Complexes in Aqueous Solutions. Mechanism of the Chromium(VI) Oxidation of Oxalic Acid. Inorganic Chemistry, 1998, 37, 3159-3166.	1.9	40
89	Activation of Molecular Oxygen during the Reactions of Chromium(VI/V/IV) with Biological Reductants:Â Implications for Chromium-Induced Genotoxicities1. Journal of the American Chemical Society, 1998, 120, 6704-6714.	6.6	114
90	Stability and Ligand Exchange Reactions of Chromium(IV) Carboxylato Complexes in Aqueous Solutions1. Inorganic Chemistry, 1997, 36, 5440-5448.	1.9	64

#	Article	IF	Citations
91	Kinetics and Mechanism of Chromium(VI) Reduction to Chromium(III) byl-Cysteine in Neutral Aqueous Solutions. Inorganic Chemistry, 1996, 35, 7709-7717.	1.9	74
92	Potassium dichromate-Adogen 464/sodium percarbonate in acetonitrile: a simple, effective, catalytic and inexpensive system for the oxidative cleavage of Î±-functionalized benzylic alcohols. Inorganica Chimica Acta, 1995, 238, 183-185.	1.2	8
93	Enantioselective allylic oxidation in the presence of the catalytic system. Tetrahedron: Asymmetry, 1995, 6, 147-156.	1.8	83
94	On the stability of the copper- (S)-proline catalyst in the enantioselective allylic acyloxylation of alkenes. Journal of Organometallic Chemistry, 1995, 494, 165-168.	0.8	25
95	A Convenient One-Step Catalytic Method for Obtaining Optically Active 2-Cyclopentenyl Benzoate from Cyclopentene. Synthetic Communications, 1995, 25, 1789-1794.	1.1	21
96	Chromium in Biology: Toxicology and Nutritional Aspects. , 0, , 145-250.		4